{"id":"ibuprofen-and-aprepitant","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Upper abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Aprepitant is a neurokinin-1 (NK1) receptor antagonist that crosses the blood-brain barrier to block substance P signaling in the chemoreceptor trigger zone and vomiting center, providing antiemetic effects. The combination targets both pain/inflammation and chemotherapy-induced nausea and vomiting (CINV).","oneSentence":"This combination uses ibuprofen to reduce inflammation and pain via COX inhibition, while aprepitant blocks substance P receptors to prevent nausea and vomiting.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:26.296Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) with concurrent pain management"},{"name":"Cancer-related pain with antiemetic support"}]},"trialDetails":[{"nctId":"NCT06317064","phase":"PHASE3","title":"Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Lahore Medical Research Center, LLP","startDate":"2024-03-15","conditions":"Primary Dysmenorrhea","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NSAIDs, Neurokinin 1 Receptor antagonist"],"phase":"phase_3","status":"active","brandName":"Ibuprofen and Aprepitant","genericName":"Ibuprofen and Aprepitant","companyName":"Lahore Medical Research Center, LLP","companyId":"lahore-medical-research-center-llp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ibuprofen to reduce inflammation and pain via COX inhibition, while aprepitant blocks substance P receptors to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) with concurrent pain management, Cancer-related pain with antiemetic support.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}